Literature DB >> 12807081

Update: global measles control and mortality reduction--worldwide, 1991-2001.

.   

Abstract

Despite international recognition of the high burden of disease associated with measles and the existence for 40 years of a safe, effective, and inexpensive vaccine, measles remains the leading cause of vaccine-preventable childhood mortality. In 1990, the World Summit for Children adopted a goal of vaccinating 90% of the world's children against measles by 2000 (1). In 2001, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) developed the Global Measles Strategic Plan for 2001-2005. The plan's objectives are 1) to decrease the annual number of measles deaths by 50% by 2005 compared with 1999 levels (875,000 deaths), 2) to achieve and maintain interruption of indigenous measles transmission in large geographic areas with elimination goals, and 3) to convene a global consultation in 2005 to review progress and assess the feasibility of global measles eradication. In May 2002, the United Nations General Assembly Special Session on Children also resolved to reduce measles deaths by 50% by 2005 compared with 1999 levels. This report describes progress toward eliminating measles worldwide. Data from WHO's Global Burden of Disease (GBD) project indicate that approximately 1.7 million vaccine-preventable childhood deaths occurred in 2000, of which 777,000 (46%) were attributed to measles. The measles deaths occurred overwhelmingly among children living in poor countries with inadequate vaccination services. To prevent these deaths, stronger political commitment is needed to provide all children worldwide with two opportunities for measles immunization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807081

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  10 in total

1.  Immunologic significance of HLA class I genes in measles virus-specific IFN-gamma and IL-4 cytokine immune responses.

Authors:  Inna G Ovsyannikova; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-12-06       Impact factor: 2.846

2.  Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.

Authors:  Chien-Hsiung Pan; Alexandra Valsamakis; Teresa Colella; Nitya Nair; Robert J Adams; Fernando P Polack; Catherine E Greer; Silvia Perri; John M Polo; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

3.  Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Guy Tam; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

Review 4.  Measles control--can measles virus inhibitors make a difference?

Authors:  Richard K Plemper; James P Snyder
Journal:  Curr Opin Investig Drugs       Date:  2009-08

5.  Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants.

Authors:  Hayley A Gans; Linda L Yasukawa; Cathryn Z Zhang; Rima Hanna Wakim; Mary Rinki; Ross Dehovitz; Ann M Arvin
Journal:  Viral Immunol       Date:  2008-06       Impact factor: 2.257

6.  Measles vaccine coverage and factors related to uncompleted vaccination among 18-month-old and 36-month-old children in Kyoto, Japan.

Authors:  Takayo Matsumura; Takeo Nakayama; Shigeru Okamoto; Hideko Ito
Journal:  BMC Public Health       Date:  2005-06-04       Impact factor: 3.295

7.  Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.

Authors:  Piyanit Tharmaphornpilas; Pornsak Yoocharean; Aim-Orn Rasdjarmrearnsook; Apiradee Theamboonlers; Yong Poovorawan
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

8.  Measles virus strain diversity, Nigeria and Democratic Republic of the Congo.

Authors:  Jacques R Kremer; Edith Nkwembe; Akeeb O Bola Oyefolu; Sheilagh B Smit; Elisabeth Pukuta; Sunday A Omilabu; Festus D Adu; Jean Jacques Muyembe Tamfum; Claude P Muller
Journal:  Emerg Infect Dis       Date:  2010-11       Impact factor: 6.883

9.  Following in the footsteps of smallpox: can we achieve the global eradication of measles?

Authors:  Oliver WC Morgan
Journal:  BMC Int Health Hum Rights       Date:  2004-03-17

10.  Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.

Authors:  Romanee Chaiwarith; Jutarat Praparattanapan; Khanuengnit Nuket; Wilai Kotarathitithum; Khuanchai Supparatpinyo
Journal:  BMC Infect Dis       Date:  2016-04-30       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.